Short answer
ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus.
ALUMIS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus
- Planned NDA submission in fourth quarter 2026 creates a key regulatory catalyst
- Prespecified subgroup analyses may influence future Phase 3 development and lupus strategy
- Potential expansion into cutaneous lupus erythematosus and Sjögren’s disease supports a broader TYK2 opportunity
- Results remain subject to regulatory acceptance, safety, efficacy, replication, funding, and commercialization risks
Item EX-99.1 · Exhibit EX-99.2
- LUMUS Phase 2b missed primary and secondary endpoints in the overall 408-patient SLE population, weakening near-term lupus prospects
- Prespecified IFNGS-high subgroup showed robust BICLA, CLASI-50, SRI-4, and LLDAS responses, supporting planned Phase 3 regulatory discussions
- IFNGS-high patients were under-represented, making overall results less reflective of Alumis’s targeted interferon-driven strategy
- Dose-dependent interferon-pathway suppression peaked at 40mg twice daily, with no new safety signals
- Psoriasis remains the nearer-term catalyst, with NDA submission still targeted for 4Q 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ALUMIS INC. 8-K filings
Get the next ALMS 8-K as it lands
Follow ALMS for push alerts, or ask the research agent what this filing means.